Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Higher Dose of Checkpoint Inhibitor Feasible in NSCLC

Publish date:: April 9, 2019

Key clinical point: Nivolumab every 4 weeks appeared comparable with every 2-week dosing in non–small cell lung cancer.

Major finding: The 6-month progression-free survival rates were 72% with each dosing regimen.

Study details: A randomized phase 3/4 trial in 363 patients with advanced non–small cell lung cancer.

Disclosures: The study was supported by Bristol-Myers Squibb. Dr. Garon reported receiving research support from Bristol-Myers Squibb and others and consulting fees from Dracen Pharmaceuticals

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,